"... They have “imaged” their first patient but not told us the “results” of that image (which is somewhat concerning?) ..."
What the result is should not be concerning to shareholders. The result will be one of three: Negative, Positive, or Unequivocal. That will be the case for the next 219 patients recruited to this trial (and the 383 in CLARIFY).
To the patient, a positive strengthens the doctor's view that the cancer has returned (since this is cancer recurrence, and the reason for imaging is to check for that - following a high or rising PSA). The patient can move to treatment. A negative reduces the level of suspicion - so they will monitor or disbelieve the result and still treat. If its unequivocal - they can try Illuccix!
CU6 Price at posting:
$2.25 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)